Many renal disease studies suffer from difficult to recruit patient populations and co-conditions such as diabetes and renally-impaired patients, making these studies difficult to enroll.
Medpace conducts trials in renally-impaired patients, including patients currently undergoing dialysis, and in patients suffering from diabetic nephropathy as well as other chronic kidney diseases (CKD).
The Medpace Difference for Nephrology Studies
Our nephrology clients benefit from:
Board-certified nephrologist with more than 26 years of experience in clinical drug development, responsible for leading several drugs from early phase development through product launch, including Teveten® and Coreg®, TQT studies for Levitra® and Vesicare®
Our thorough understanding of the complex metabolic conditions that cause CKD, as well as the medical complications experienced by patients with CKD and early stage renal disease (ESRD)
International network of nephrology investigative sites which regularly participate and successfully enroll in nephrology studies
A seasoned clinical operations staff with specific experience in conducting nephrology trials